- About Us
- Phase I
- Phase II
- Data Services
- Core Laboratories
- Media Center
Merck has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.
Bone Therapeutics, a Belgium regenerative therapy company addressing unmet medical needs releated to bone diseases and orthopaedics, and Kasios, a French synthetic bone substitute specialist, have announce a two-year collaboration to develop a novel product for spinal fusion procedures. The collaboration combines Bone Therapeutics' allogeneic osteoblastic cell therapy product ALLOB with Kasios's synthetic micro-granules bone substitute. The project is subsidized by the government of the Walloon Region.
Dublin-based Actavis, a global, integrated, specialty pharmaceutical company has announced it will acquire Allergan, a multi-specialty healthcare company based in Irvine, Calif., for approximately $66 billion, or $219 per share.
Typically, when a major shift occurs in how things are managed, there is an adjustment period during which users embrace the new change but are reluctant to let go of some long-standing parts of the old way.
Recipharm, a Swedish pharmaceutical contract development and manufacturing organization (CDMO), has acquired Lisbon, Portugal-based CDMO Lusomedicamenta Sociedade Técnica Farmacêutica.
Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has acquired Micron Technologies, a Boise, Idaho-based global provider of particle size engineering technologies.
Working with institutions in Research Triangle Park and throughout North Carolina, U.S. biopharmaceutical research companies have conducted over 6,000 clinical trials of new medicines in the state since 1999, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).
The Center for Information and Study on Clinical Research Participation (CISCRP) and the Association for Clinical Research Professionals (ACRP), two independent, nonprofit organizations based Boston, Mass. and Alexandria, Va., respectively, have announced the upcoming Medical Heroes Appreciation 5K Run & Walk in Salt Lake City, Utah, to celebrate those who volunteer to participate in clinical research and raise awareness about the importance of clinical research in advancing public health.
Precision Therapeutics has changed its name to Helomics, a Pittsburgh, Pa.-based, privately held comprehensive personalized healthcare company that develops next-generation diagnostics for the oncology field.
Global CRO Parexel International has opened its new European Coordination Hub and Distribution Center in Berlin-Schönefeld, Germany.
The European CRO Federation (EUCROF), which represents 300 member CROs, has released proposals on the early publication of clinical trial information, balancing the public’s need for transparency and innovators’ intellectual property and confidentiality rights.
ActiGraph, a Pensacola, Fla.-based provider of objective physical activity and sleep/wake measurement solutions for the global research community and pharmaceutical industry, has released the ActiGraph GT9X Link activity monitor. The redesigned ActiGraph Link expands upon the company’s scientifically validated physical activity and sleep measurement platform with a rich feature set that delivers an improved subject experience along with multiple new channels of sensor data captured by a gyroscope, magnetometer and secondary accelerometer.
The first research collaboration in the U.K. among a hospital, university and community pharmacist is taking place through a project from Liverpool John Moores University (LJMU), the Royal Liverpool and Broadgreen University Hospitals NHS Trust and LloydsPharmacy. The collaboration aims to improve the way patients use their medicines outside hospitals and will be carried out in the newly opened Center for Pharmacy Innovation at the LJMU School of Pharmacy and Biomolecular Sciences.
The Global Health Innovative Technology (GHIT) Fund and the Embassy of Japan have called for greater cross-border collaboration to ensure global preparedness for the inevitable resurgence of infectious diseases, including tuberculosis, malaria, HIV/AIDS and neglected tropical diseases.
ArQule, a Woburn, Mass.-based biotech company engaged in the R&D of next-generation, small-molecule cancer therapeutics, has formed an agreement with the National Human Genome Research Institute (NHGRI) of the NIH, providing for the clinical development of ARQ 092, an orally available, selective small molecule inhibitor of AKT, in Proteus syndrome, a rare disease characterized by overgrowth of the skeleton, skin, adipose tissue and central nervous system.
Status: Recruiting, Condition Summary: Alzheimer Disease; Hearing Loss
Status: Recruiting, Condition Summary: Alzheimer's Disease
PRA Health Sciences launched its initial public offering this morning, raising $306 million from the sale of nearly 17 million shares at $18 per share—below plans it announced in September to raise up to $375 million.
The FDA has accepted for filing Actavis' supplemental New Drug Application (sNDA) for Saphris (asenapine) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients 10 to 17 years of age. Actavis' sNDA for Saphris has been granted priority review status by the FDA.
Cell Source, an immunotherapy and regenerative medicine company, has announced its Megadose Drug Combination has been cleared for human clinical trials in Italy. Cell Source's proprietary Megadose Drug Combination is expected to increase bone marrow transplantation (BMT) success and survival.